Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc., a Canadian life sciences firm, has announced an update to its fundraising efforts, which now expects to raise approximately C$19.2 million. Key company executives, including CEO Carolyn Cross, are participating by subscribing to a significant number of shares, highlighting confidence in the firm’s future. The funds will be used to advance clinical trials for its Steriwave nasal photodisinfection system and support other business operations.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.